Two Picks that Fit the Theme for Jordan Opportunity
Jordan Opportunity manager Jerry Jordan on the fund's stake in Myriad Genetics and NetEase.
Jordan Opportunity manager Jerry Jordan on the fund's stake in Myriad Genetics and NetEase.
Ryan Leggio: I know you run a relatively concentrated portfolio. Are there any names in particular that you've bought recently that just have terrific risk-adjusted dynamics?
Jerry Jordan: Sure. I mentioned Myriad Genetics. This is an incredible company. They've got a number of products that sort of fall into the OB/GYN space. Their big one is called BRAC Analysis, which is their own proprietary diagnostic test for telling whether you have a biological precursor potential for breast cancer. With the idea that if you can catch this early enough you can do, say, a lumpectomy or something so that people don't have to have a mastectomy. Or in situations where maybe there is a big family history, you can really stay on top of it.
Recently, sales have slowed down because fewer people are going to the doctor. They're concerned about their co-pays. They don't have the money for co-pays. They've lost their jobs so their medical coverage may not be as strong, so they're not going to spend a couple hundred bucks out of pocket for a test like this.
But I think inevitably, this will start to turn. As we get out of this year, comparisons get easier. Whatever health-care plan comes through, if anything does, whatever plan comes through, I think it's really going to focus on diagnostic.
<TRANSCRIPT>
So if the government is going to pick up 30 million lives, it would love to find out if you have got prostate cancer in year two instead of seven, if you have got breast cancer in year two instead of year seven. Why? Because it's better for the patient, and it's better for the payer.
And so I think you are going to see a real move into that. And the business just gets better as you look out. It is also not really strongly economically sensitive. The valuation is reasonable.
Another name we have been buying in here is a company called NetEase I said I wasn't a big fan of technology, but one part of technology we really own right now--and I think this gets to our ability to find really interesting areas to invest in--is we've got about 6% to 8% in, I don't know, four or five Chinese video game and Internet companies. They're listed in the United States, but the businesses are in China.
One company, NetEase, has got a couple of games that were delayed that are now coming out that should really drive growth over the next year, year and a half. It is a 12, 13 multiple stock. I think it will grow 30% a year for the next two years.
And I think China's just going to continue to boom along here. Three years from now, I don't know. But for the next 18-24 months. They're going to make things happen.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.